Functional comparison of plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay

Infection and Immunity

Volumn 81, Issue 12, 2013, Pages 4377-4382

  Miura, Kazutoyo ^a   Takashima, Eizo ^b   Deng, Bingbing ^a   Tullo, Gregory ^a   Diouf, Ababacar ^a   Moretz, Samuel E ^a   Nikolaeva, Daria ^a   Diakite, Mahamadou ^c   Fairhurst, Rick M ^a   Fay, Michael P ^a   Long, Carole A ^a   Tsuboi, Takafumi ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b EHIME UNIVERSITY   (Japan)

^c UNIVERSITY OF BAMAKO   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 720; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANOPHELES STEPHENSI; ARTICLE; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALARIA; MALARIA CONTROL; MALI; MOUSE; NONHUMAN; OOCYST; OUTBRED MOUSE STRAIN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 84890202599     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01056-13     Document Type: Article

References (22)

1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431.
2. The malERA Consultative Group on Vaccines. 2011. A research agenda for malaria eradication: vaccines. PLoS Med. 8:e1000398. doi:10.1371/journal.pmed.1000398.
3. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. 2012. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284-2295.
4. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A. 2005. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23:3131-3138.
5. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3:e2636. doi:10.1371/journal.pone.0002636.
6. Pradel G. 2007. Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies. Parasitology 134:1911-1929.
7. Tsuboi T, Takeo S, Iriko H, Jin L, Tsuchimochi M, Matsuda S, Han ET, Otsuki H, Kaneko O, Sattabongkot J, Udomsangpetch R, Sawasaki T, Torii M, Endo Y. 2008. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 76:1702-1708.
8. Tachibana M, Wu Y, Iriko H, Muratova O, Macdonald NJ, Sattabongkot J, Takeo S, Otsuki H, Torii M, Tsuboi T. 2011. N-terminal prodomain of Pfs230 synthesized using cell-free system is sufficient to induce the complement dependent malaria transmission-blocking activity. Clin. Vaccine Immunol. 18:1343-1350.
9. Miura K, Deng B, Tullo G, Diouf A, Moretz SE, Locke E, Morin M, Fay MP, Long CA. 2013. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS One 8:e57909. doi:10.1371/journal.pone.0057909.
10. Blagborough AM, Sinden RE. 2009. Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. Vaccine 27:5187-5194.
11. Williamson KC, Keister DB, Muratova O, Kaslow DC. 1995. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol. Biochem. Parasitol. 75:33-42.
12. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. 2008. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26:193-200.
13. Singh K, Gitti RK, Diouf A, Zhou H, Gowda DC, Miura K, Ostazeski SA, Fairhurst RM, Garboczi DN, Long CA. 2010. Subdomain 3 of Plasmodium falciparum VAR2CSA DBL3X is identified as a minimal chondroitin sulfate A binding region. J. Biol. Chem. 285:24855-24862.
14. Skaug H, Fournier D, Nielsen A, Magnusson A, Bolker B. 2012. Generalized linear mixed models usingADModel Builder. TheglmmADMBR package version 0.7.3.
15. Wright SP. 1992. Adjusted p-values for simultaneous inference. Biometrics 48:1005-1013.
16. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74-76.
17. Tsuboi T, Takeo S, Arumugam TU, Otsuki H, Torii M. 2010. The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery. Acta Trop. 114:171-176.
18. Rui E, Fernandez-Becerra C, Takeo S, Sanz S, Lacerda MV, Tsuboi T, del Portillo HA. 2011. Plasmodium vivax: comparison of immunogenicity among proteins expressed in the cell-free systems of Escherichia coli and wheat germ by suspension array assays. Malar. J. 10:192. doi:10.1186/1475-2875-10-192.
19. Arumugam TU, Takeo S, Yamasaki T, Thonkukiatkul A, Miura K, Otsuki H, Zhou H, Long CA, Sattabongkot J, Thompson J, Wilson DW, Beeson JG, Healer J, Crabb BS, Cowman AF, Torii M, Tsuboi T. 2011. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect. Immun. 79:4523-4532.
20. Sakamoto H, Takeo S, Maier AG, Sattabongkot J, Cowman AF, Tsuboi T. 2012. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine 30:1972-1980.
21. Chowdhury DR, Angov E, Kariuki T, Kumar N. 2009. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 4:e6352. doi:10.1371/journal.pone.0006352.
22. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, Jacobs-Lorena M. 2007. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc. Natl. Acad. Sci. U. S. A. 104:13461-13466.